5mg/2ml ampoules (IV, IM)

Executive Summary

(April 5, 2023)

Executive Summary

Droperidol is a first generation antipsychotic (so-called typical antipsychotics, same class as haloperidol) that acts as a D2 dopamine receptor antagonist. Droperidol also has some histamine and serotonin antagonist properties (17). 


Adult dose for undifferentiated agitation in the ED

5-10mg IM

Adult dose for migraine, acute vertigo, nausea or vomiting and cannabinoid hyperemesis
1.25-2.5mg IV or IM

Adult dose

Adult dose for undifferentiated agitation in the ED (7, 19)

5-10mg IM

Adult dose for migraine, acute vertigo, nausea or vomiting and cannabinoid hyperemesis (23, 3, 5, 16)

1.25-2.5mg IV or IM



Usage in the ED

Usage in the Emergency Department

Mechanism of action

Droperidol is a first-generation antipsychotic that has prominent dopamine antagonism. Its effects include(4, 8): 



Warnings and Precautions

Questioning of the US-FDA Black Box Warning

A copious amount of clinical data, review articles and society statements have emerged over the last decade defending droperidol safety when used properly and in the doses that usually are sufficiently needed in the ED (11, 18). 

Society positions, review articles, expert opinion:

Droperidol is Back by Reuben Strayer

Pregnancy and lactation




® 2023 EMDrugs. All rights reserved.



This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 


Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 


The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 


For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team